Long-Term Patient-Reported Outcomes Data from the JAVELIN Bladder 100 Trial in Patients with Advanced Urothelial Carcinoma
The JAVELIN Bladder 100 trial has previously shown a survival benefit with switch maintenance avelumab anti-PD-1 therapy in patients who had a response or stable disease after platinum-based chemotherapy. In this MEDtalk, Dr. Petros Grivas presents the long-term data presented at ASCO GU 2024, which confirmed that the significant prolongation in overall and progression-free survival was achieved with a significant preservation to the patient’s quality of life.
